Schrödinger (SDGR) Q2 2026: Hosted Revenue Jumps to 47% as Bunsen Drives Platform Adoption
Schrödinger’s accelerated shift to hosted software contracts and the launch of its AI co-scientist Bunsen are redefining its business model and customer engagement, even as the company navigates transitional revenue headwinds. Robust ACV growth and operational discipline support a strategic pivot toward scalable, recurring revenue, with product innovation and pharma sector recovery fueling optimism for the second half. Investors should track the durability of hosted adoption and the monetization of new AI-driven capabilities as key levers for future growth.
Summary
- Hosted Licensing Reshapes Revenue Timing: Transition to hosted contracts accelerates recurring revenue, but temporarily dampens reported top line.
- Bunsen AI Co-Scientist Expands Platform Reach: Early adoption by large pharma and internal teams signals broader industry traction.
- Expense Discipline and Pharma Recovery Strengthen Outlook: Cost controls and improved biotech funding environment support continued margin improvement.
Business Overview
Schrödinger is a computational science company specializing in physics-based software for molecular discovery, primarily targeting drug design and materials science. The company operates two main segments: software, which provides simulation and modeling tools to life sciences and industrial customers, and drug discovery, which advances its own and partnered therapeutic programs. Revenue is generated through software licensing, hosted platform subscriptions, milestone payments, and royalties from co-invented drugs.
Performance Analysis
Schrödinger delivered strong annual contract value (ACV) growth of 27% year over year, driven by broad-based demand from large pharma, biotech, and materials science customers. The company’s hosted revenue mix rose to 47% of software sales, up from 31% a year ago, reflecting a deliberate and accelerated transition to recurring, ratable revenue recognition. This shift, while strategically beneficial for long-term predictability, resulted in a temporary drag on reported revenue—management noted that each 1% increase in hosted mix reduces recognized revenue by $2 to $3 million, depending on contract timing and duration.
Drug discovery revenue nearly doubled, buoyed by a $10 million milestone from Ajax Therapeutics, while contribution revenue fell due to the wind-down of initial Gates Foundation support. Gross margin on software compressed to 71% from 76% last year, a function of the revenue model transition rather than underlying demand. Operating expenses declined 6% year over year, reflecting lower headcount and professional services, and the company posted positive net income on the back of a one-time gain from Eli Lilly’s Ajax acquisition.
- Recurring Revenue Focus: Hosted contracts now account for nearly half of software revenue, supporting long-term visibility but creating near-term revenue headwinds.
- ACV Growth Broad-Based: Top 20 pharma, biotech, and materials science all contributed to robust ACV gains, signaling healthy end-market demand.
- Expense Controls Materialize: Lower personnel and CRO costs drove a 6% reduction in operating expenses, aiding the path to profitability.
Schrödinger’s balance sheet remains strong with $419 million in cash and marketable securities, providing flexibility to invest in R&D and software innovation while weathering near-term revenue variability from the hosted transition.
Executive Commentary
"The biopharma industry is increasingly recognizing that a computationally driven, predict-first approach is a critical driver for accelerating drug discovery timelines and improving probabilities of success. Our ACV growth of 27%, driven by broad-based demand, reflects this ongoing shift."
Ramy Farid, Chief Executive Officer
"Our year-over-year revenue growth continues to be impacted by our planned, accelerated transition to hosted licenses, for which revenue is recognized ratably over the life of the contract, rather than mostly upfront. We are pleased with the conversion dynamics we are seeing so far, and our priority remains converting customers as their contracts come up for renewal."
Richie Jain, Chief Financial Officer
Strategic Positioning
1. Hosted Platform Model: Recurring Revenue and Customer Stickiness
Schrödinger’s deliberate push to hosted software contracts—now at 47% of software revenue—signals a strategic pivot toward recurring, predictable revenue streams. This model, which recognizes revenue over the contract term, enhances customer retention and usage monitoring, but requires investors to look past short-term top line softness to assess underlying business health.
2. Bunsen AI Co-Scientist: Expanding the TAM and User Base
Bunsen, the company’s agentic AI co-scientist, is driving both internal productivity and external adoption, with Bristol Myers Squibb (BMS) deploying the platform across its research organization. Bunsen enables complex, multi-step workflows and democratizes access to advanced simulations, broadening Schrödinger’s addressable market and deepening integration within large pharma customers.
3. Product Innovation: Predictive Toxicology and Beyond
Schrödinger’s predictive toxicology solution leverages advanced physics-based models to identify off-target binding risks early in the drug discovery process. This not only accelerates candidate optimization but also unlocks new budget pools within pharma, as evidenced by commercial evaluations and ACV contributions from the product. Management views ongoing R&D as a key lever for future product launches and market expansion.
4. Pharma Sector Recovery: Improved Biotech Funding Environment
Management highlighted a marked improvement in biotech funding and IPO activity compared to last year, which is supporting increased demand from the sector. This recovery is expected to sustain customer growth and platform adoption, reducing the headwinds seen in 2025.
5. Operational Discipline: Cost Controls and Margin Focus
Expense management remains a priority, with reductions in headcount and external services producing tangible operating leverage. The company is leveraging Bunsen internally to further boost productivity, particularly in its therapeutics portfolio, supporting margin expansion as revenue mix shifts.
Key Considerations
Schrödinger’s second quarter underscores a business in strategic transition, balancing the near-term costs of a hosted model pivot with the long-term rewards of scalable, recurring revenue and AI-driven platform adoption.
Key Considerations:
- Hosted Revenue Model Implications: Investors must look through near-term revenue compression to assess the quality and durability of recurring revenue growth.
- Bunsen Adoption as a Growth Catalyst: Early wins with large pharma validate the platform, but broader industry uptake and monetization remain key watchpoints.
- Pharma and Biotech End Market Health: Improved funding and IPO activity support demand, but sector cyclicality could re-emerge as a risk.
- Product Pipeline Depth: Ongoing R&D investment is critical for sustaining ACV growth through new product launches and expanded customer budgets.
- Operational Efficiency: Continued cost discipline will be necessary to offset margin pressure from the hosted transition and support profitability targets.
Risks
Schrödinger faces transitional execution risk as it accelerates the shift to hosted contracts, with near-term revenue recognition lagging underlying ACV growth. Key risks include slower than anticipated customer conversion to hosted, competitive pressure from alternative AI and simulation platforms, and potential delays in milestone or royalty revenue from therapeutics partnerships. Macro volatility in biotech funding and pharma R&D budgets could also impact growth trajectories, particularly if sector sentiment reverses.
Forward Outlook
For Q3 2026, Schrödinger guided to:
- ACV excluding contribution of $41 to $45 million (compared to $38.3 million in Q3 2025, which included $2.2 million of contribution ACV)
For full-year 2026, management maintained guidance:
- ACV of $218 to $228 million, representing 10% to 15% growth over 2025
- Drug discovery revenue of $65 to $75 million
Management cited several positive drivers:
- Ongoing conversion of customers to hosted contracts, with Q4 expected to be the largest quarter for renewals
- Strong pipeline of opportunities expected to close in the second half of the year, particularly among large pharma customers
Takeaways
Schrödinger’s Q2 2026 results reflect a business in the midst of a high-stakes transition, with hosted software adoption and AI-driven innovation at the core of its long-term value proposition.
- Hosted Transition Drives Predictability: The shift to hosted contracts will support more stable, recurring revenue, but investors must be patient as reported revenue lags underlying growth.
- Bunsen and Predictive Tox Unlock New Growth Vectors: Early traction with Bunsen and new product launches like predictive toxicology are expanding the platform’s reach and budget access within pharma.
- Watch for Hosted Adoption Pace and Product Monetization: The speed of hosted customer conversion and the revenue impact of new AI-enabled products will be the most important signals for future quarters.
Conclusion
Schrödinger’s second quarter demonstrates strategic clarity and operational discipline as it pursues a platform-centric, recurring revenue model anchored by AI-driven innovation. The company’s ability to convert hosted adoption and new product launches into durable, high-margin growth will determine the pace and magnitude of future value creation.
Industry Read-Through
Schrödinger’s results highlight a broader industry trend toward cloud-based, AI-powered scientific platforms in both life sciences and materials discovery. The transition to hosted, subscription-based models is becoming the norm across scientific software, with revenue recognition lag a common feature for investors to monitor. Early adoption of AI co-scientist tools by large pharma signals a shift toward automation and parallelization of complex R&D workflows, raising the bar for competitive differentiation and integration. Other platform providers should note the importance of product innovation and operational discipline in successfully navigating the transition to recurring revenue models.